OpenLB
Open Library of Bioscience
Advanced Search
Microbial biotechnology
07, 2023;16 (7): 1456-1474.

Novel antimicrobial strategies to treat multi-drug resistant Staphylococcus aureus infections.

Edward J A Douglas, Sri W Wulandari, Scott D Lovell, Maisem Laabei
Author Information
  1. Edward J A Douglas: Department of Life Sciences, University of Bath, Bath, UK. ORCID
  2. Sri W Wulandari: Department of Life Sciences, University of Bath, Bath, UK.
  3. Scott D Lovell: Department of Life Sciences, University of Bath, Bath, UK.
  4. Maisem Laabei: Department of Life Sciences, University of Bath, Bath, UK. ORCID
PMID: 37178319 DOI: 10.1111/1751-7915.14268

Abstract

Antimicrobial resistance is a major obstacle for the treatment of infectious diseases and currently represents one of the most significant threats to global health. Staphylococcus aureus remains a formidable human pathogen with high mortality rates associated with severe systemic infections. S. aureus has become notorious as a multidrug resistant bacterium, which when combined with its extensive arsenal of virulence factors that exacerbate disease, culminates in an incredibly challenging pathogen to treat clinically. Compounding this major health issue is the lack of antibiotic discovery and development, with only two new classes of antibiotics approved for clinical use in the last 20 years. Combined efforts from the scientific community have reacted to the threat of dwindling treatment options to combat S. aureus disease in several innovative and exciting developments. This review describes current and future antimicrobial strategies aimed at treating staphylococcal colonization and/or disease, examining therapies that show significant promise at the preclinical development stage to approaches that are currently being investigated in clinical trials.

References

  1. PLoS One. 2013 Dec 09;8(12):e82814 [PMID: 24349368]
  2. Nature. 2016 Jul 27;535(7613):511-6 [PMID: 27466123]
  3. J Med Chem. 2011 Aug 25;54(16):5786-95 [PMID: 21732630]
  4. J Wound Care. 2009 Jun;18(6):237-8, 240-3 [PMID: 19661847]
  5. Antimicrob Agents Chemother. 2015 Aug;59(8):4845-55 [PMID: 26033735]
  6. Mater Sci Eng C Mater Biol Appl. 2021 Jul;126:112167 [PMID: 34082968]
  7. J Infect Dis. 2005 Jun 15;191(12):2149-52 [PMID: 15898002]
  8. Front Immunol. 2018 Oct 16;9:2252 [PMID: 30459750]
  9. Front Microbiol. 2019 Dec 03;10:2762 [PMID: 31849901]
  10. Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0144121 [PMID: 34807760]
  11. Nat Microbiol. 2018 Apr;3(4):415-422 [PMID: 29434326]
  12. Ann N Y Acad Sci. 2013 Jan;1277:139-58 [PMID: 23215859]
  13. Antimicrob Agents Chemother. 2020 Dec 16;65(1): [PMID: 33106269]
  14. J Antimicrob Chemother. 2007 Sep;60(3):568-74 [PMID: 17606482]
  15. Cell. 2017 Nov 30;171(6):1354-1367.e20 [PMID: 29103614]
  16. Bioorg Chem. 2019 Oct;91:103169 [PMID: 31398602]
  17. J Antimicrob Chemother. 2009 Dec;64(6):1130-8 [PMID: 19825818]
  18. Mol Cancer Ther. 2002 Mar;1(5):347-55 [PMID: 12489851]
  19. Antimicrob Agents Chemother. 2012 Nov;56(11):5865-74 [PMID: 22948878]
  20. J Med Chem. 2022 May 12;65(9):6612-6630 [PMID: 35482444]
  21. Mol Microbiol. 2011 Oct;82(1):9-20 [PMID: 21902734]
  22. Chemistry. 2020 May 15;26(28):6247-6256 [PMID: 32166806]
  23. Philos Trans R Soc Lond B Biol Sci. 2016 Nov 5;371(1707): [PMID: 27672152]
  24. Antimicrob Agents Chemother. 2013 Jun;57(6):2743-50 [PMID: 23571534]
  25. J Nat Prod. 2020 Sep 25;83(9):2597-2606 [PMID: 32921049]
  26. ACS Chem Biol. 2017 Jul 21;12(7):1947-1955 [PMID: 28621933]
  27. Antibiotics (Basel). 2021 Dec 07;10(12): [PMID: 34943714]
  28. J Biol Chem. 1993 May 25;268(15):11086-9 [PMID: 8098708]
  29. Lancet. 2022 Feb 12;399(10325):629-655 [PMID: 35065702]
  30. Antimicrob Agents Chemother. 2014 Aug;58(8):4411-9 [PMID: 24841266]
  31. Nature. 2022 Aug;608(7922):390-396 [PMID: 35922513]
  32. Antimicrob Agents Chemother. 2012 Aug;56(8):4478-82 [PMID: 22585222]
  33. MMWR Morb Mortal Wkly Rep. 2019 Mar 08;68(9):214-219 [PMID: 30845118]
  34. Drugs R D. 2022 Jun;22(2):113-117 [PMID: 35175568]
  35. Antimicrob Agents Chemother. 2012 Jan;56(1):83-91 [PMID: 22005998]
  36. Annu Rev Microbiol. 2001;55:305-32 [PMID: 11544358]
  37. Int J Med Microbiol. 2014 Mar;304(2):204-14 [PMID: 24462009]
  38. Virulence. 2014 Jan 1;5(1):226-35 [PMID: 23973944]
  39. J Org Chem. 2018 Jul 6;83(13):6924-6935 [PMID: 29019678]
  40. Antimicrob Agents Chemother. 2000 Jun;44(6):1549-55 [PMID: 10817707]
  41. Clin Microbiol Rev. 2015 Jul;28(3):603-61 [PMID: 26016486]
  42. Front Cell Infect Microbiol. 2022 Jun 17;12:907314 [PMID: 35782148]
  43. J Antibiot (Tokyo). 2020 Jun;73(6):329-364 [PMID: 32152527]
  44. Nat Rev Microbiol. 2021 Apr;19(4):225-240 [PMID: 33093661]
  45. Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):6968-73 [PMID: 19359494]
  46. Pharmaceuticals (Basel). 2021 Oct 12;14(10): [PMID: 34681262]
  47. Nat Rev Dis Primers. 2018 May 31;4:18033 [PMID: 29849094]
  48. Nature. 2015 Nov 19;527(7578):323-8 [PMID: 26536114]
  49. Trends Microbiol. 2001 Dec;9(12):605-10 [PMID: 11728874]
  50. J Antimicrob Chemother. 2012 Sep;67(9):2143-51 [PMID: 22615298]
  51. FEMS Microbiol Lett. 2004 Feb 16;231(2):177-84 [PMID: 14987762]
  52. Antimicrob Agents Chemother. 2011 Apr;55(4):1764-7 [PMID: 21263051]
  53. Antimicrob Agents Chemother. 2015 Dec 28;60(3):1656-66 [PMID: 26711778]
  54. Science. 2008 Sep 19;321(5896):1673-5 [PMID: 18801997]
  55. PLoS One. 2020 Apr 14;15(4):e0231573 [PMID: 32287316]
  56. Trends Microbiol. 2019 Jan;27(1):26-38 [PMID: 30031590]
  57. Antimicrob Agents Chemother. 2016 Jun 20;60(7):4063-72 [PMID: 27114278]
  58. Antimicrob Agents Chemother. 2009 Aug;53(8):3544-8 [PMID: 19487444]
  59. Chem Rev. 2002 Dec;102(12):4549-80 [PMID: 12475201]
  60. Elife. 2022 Jan 19;11: [PMID: 35044295]
  61. J Biol Chem. 2004 Sep 24;279(39):40802-6 [PMID: 15226303]
  62. Antimicrob Agents Chemother. 2014 Sep;58(9):5136-45 [PMID: 24936592]
  63. Pharmacol Ther. 2006 Oct;112(1):71-105 [PMID: 16714062]
  64. Sci Transl Med. 2016 Mar 9;8(329):329ra32 [PMID: 26962156]
  65. Antimicrob Agents Chemother. 2007 Jun;51(6):2070-7 [PMID: 17438056]
  66. mBio. 2023 Feb 28;14(1):e0247822 [PMID: 36507833]
  67. Front Cell Infect Microbiol. 2012 Apr 24;2:43 [PMID: 22919634]
  68. N Engl J Med. 1998 Aug 20;339(8):520-32 [PMID: 9709046]
  69. Int J Infect Dis. 2022 Sep;122:405-411 [PMID: 35728748]
  70. Nature. 2020 Feb;578(7796):582-587 [PMID: 32051588]
  71. Front Microbiol. 2022 Aug 22;13:948343 [PMID: 36071957]
  72. Curr Opin Microbiol. 2019 Oct;51:72-80 [PMID: 31733401]
  73. Eur J Clin Microbiol Infect Dis. 1989 Nov;8(11):943-50 [PMID: 2532132]
  74. Mol Microbiol. 2011 Apr;80(2):290-9 [PMID: 21306448]
  75. Antimicrob Agents Chemother. 2015 Jan;59(1):145-51 [PMID: 25331699]
  76. J Bacteriol. 1984 May;158(2):513-6 [PMID: 6563036]
  77. JAMA Otolaryngol Head Neck Surg. 2019 Aug 01;145(8):723-729 [PMID: 31219531]
  78. Nat Commun. 2019 Jun 21;10(1):2730 [PMID: 31227691]
  79. J Biol Chem. 2020 Jun 26;295(26):8736-8745 [PMID: 32376690]
  80. Chem Biol. 2009 Aug 28;16(8):837-48 [PMID: 19716474]
  81. J Antibiot (Tokyo). 2015 Mar;68(3):158-64 [PMID: 25269464]
  82. Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3531-6 [PMID: 23401520]
  83. J Chem Inf Model. 2022 May 23;62(10):2586-2599 [PMID: 35533315]
  84. Emerg Top Life Sci. 2021 Nov 12;5(5):637-641 [PMID: 34723318]
  85. Nat Chem Biol. 2016 Dec;12(12):1004-1006 [PMID: 27748750]
  86. PLoS Pathog. 2011 Sep;7(9):e1002217 [PMID: 21909268]
  87. J Orthop Res. 2020 Dec;38(12):2657-2663 [PMID: 32484998]
  88. Genes Dev. 2010 Sep 1;24(17):1893-902 [PMID: 20713508]
  89. Microb Biotechnol. 2023 Jul;16(7):1456-1474 [PMID: 37178319]
  90. Annu Rev Microbiol. 2013;67:313-36 [PMID: 24024634]
  91. Health Policy. 2017 Oct;121(10):1025-1030 [PMID: 28888660]
  92. Curr Top Microbiol Immunol. 2017;409:95-120 [PMID: 26667044]
  93. Annu Rev Microbiol. 2014;68:81-100 [PMID: 24819367]
  94. Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):77-81 [PMID: 1898779]
  95. Nature. 2020 Jun;582(7811):294-297 [PMID: 32523118]
  96. Med Res Rev. 2019 Sep;39(5):2000-2025 [PMID: 30887551]
  97. FEBS J. 2021 Feb;288(4):1091-1106 [PMID: 32681661]
  98. Science. 2008 Mar 7;319(5868):1391-4 [PMID: 18276850]
  99. PLoS One. 2022 Sep 16;17(9):e0274815 [PMID: 36112657]
  100. Lancet Infect Dis. 2019 Jan;19(1):56-66 [PMID: 30409683]
  101. Antimicrob Agents Chemother. 2020 Sep 21;64(10): [PMID: 32747361]
  102. Int J Antimicrob Agents. 2013 Feb;41(2):156-61 [PMID: 23276502]
  103. Curr Opin Microbiol. 2007 Oct;10(5):461-72 [PMID: 17904412]
  104. Annu Rev Biochem. 1984;53:749-90 [PMID: 6206782]
  105. J Membr Biol. 2011 Jan;239(1-2):27-34 [PMID: 21225255]
  106. Int J Antimicrob Agents. 2019 Jan;53(1):16-21 [PMID: 30236954]
  107. Virulence. 2021 Dec;12(1):547-569 [PMID: 33522395]
  108. Peptides. 2006 Apr;27(4):649-60 [PMID: 16274847]
  109. mBio. 2015 Jan 27;6(1): [PMID: 25626904]
  110. Angew Chem Int Ed Engl. 2019 Jul 1;58(27):9234-9238 [PMID: 31059155]
  111. N Engl J Med. 2001 Jan 4;344(1):11-6 [PMID: 11136954]
  112. J Bacteriol. 2001 Apr;183(8):2662-6 [PMID: 11274127]
  113. FEMS Microbiol Rev. 2008 Mar;32(2):259-86 [PMID: 18266855]
  114. Nature. 2015 Jan 22;517(7535):455-9 [PMID: 25561178]
  115. Antimicrob Agents Chemother. 2012 Sep;56(9):4662-70 [PMID: 22710113]
  116. Open Microbiol J. 2013;7:59-71 [PMID: 23569469]
  117. Antimicrob Agents Chemother. 2019 Mar 27;63(4): [PMID: 30670417]
  118. Cold Spring Harb Perspect Med. 2016 Aug 01;6(8): [PMID: 27329032]
  119. Science. 1944 Jun 2;99(2579):452-3 [PMID: 17798398]
  120. Antimicrob Agents Chemother. 2019 May 24;63(6): [PMID: 30910894]
  121. Antimicrob Agents Chemother. 2015 Dec 28;60(3):1695-701 [PMID: 26711777]
  122. Biochem Pharmacol. 2013 Dec 15;86(12):1699-707 [PMID: 24148278]
  123. J Am Chem Soc. 2018 Jan 24;140(3):876-879 [PMID: 29300473]

MeSH Term

Drug Resistance, Multiple, Bacterial
Staphylococcus aureus
Antimicrobial Cationic Peptides
Biological Products
Anti-Bacterial Agents
Adjuvants, Pharmaceutic
Drug Synergism
Immunoconjugates
Phage Therapy
Drug Development
Staphylococcal Infections
Humans

Chemicals

Antimicrobial Cationic Peptides
Biological Products
Anti-Bacterial Agents
Adjuvants, Pharmaceutic
Immunoconjugates
Journal Article Research Support, Non-U.S. Gov't Review
Article has an altmetric score of 27

Word Cloud

Created with Highcharts 10.0.0aureusdiseasemajortreatmentcurrentlysignificanthealthStaphylococcuspathogeninfectionsSresistanttreatdevelopmentclinicalantimicrobialstrategiesAntimicrobialresistanceobstacleinfectiousdiseasesrepresentsonethreatsglobalremainsformidablehumanhighmortalityratesassociatedseveresystemicbecomenotoriousmultidrugbacteriumcombinedextensivearsenalvirulencefactorsexacerbateculminatesincrediblychallengingclinicallyCompoundingissuelackantibioticdiscoverytwonewclassesantibioticsapproveduselast20 yearsCombinedeffortsscientificcommunityreactedthreatdwindlingoptionscombatseveralinnovativeexcitingdevelopmentsreviewdescribescurrentfutureaimedtreatingstaphylococcalcolonizationand/orexaminingtherapiesshowpromisepreclinicalstageapproachesinvestigatedtrialsNovelmulti-drug

Similar Articles

Cited By (17)